Contemporary reviewArrhythmias in the muscular dystrophies
Introduction
The muscular dystrophies are a group of inherited skeletal muscle diseases. Most also have direct effects on cardiac muscle, with manifestations including heart failure, conduction disease, atrial and ventricular arrhythmias, and sudden death. With multidisciplinary care, patients are surviving to older ages, paradoxically leading to a higher risk of symptomatic cardiac involvement. Electrophysiologists are asked to be part of the team evaluating and treating patients because of the risk of arrhythmias and sudden death. An issue that arises is whether the patient's condition necessitates prophylactic pacemaker or implantable cardioverter-defibrillator (ICD) placement. In this review, the muscular dystrophies that more commonly manifest cardiac and arrhythmia involvement are evaluated and the literature assessing device use is examined. Table 1 summarizes relevant information useful in evaluating the muscular dystrophy patient.
Section snippets
Nomenclature, genetic basis, and cardiac pathology
A comprehensive review of the molecular pathophysiology of muscular dystrophies is beyond the scope of the article. However, knowledge of the relationship between the genetic basis of these diseases and the skeletal and cardiac muscle pathology can assist the clinician in understanding cardiac phenotypes.
Duchenne and Becker muscular dystrophies are X-linked recessive disorders in which a mutation is present in the dystrophin gene.1, 2 Duchenne is the most common muscular dystrophy. The
Noncardiac clinical considerations relevant to the electrophysiologist
Progressive skeletal muscle involvement can lead to loss of ambulation and later to respiratory failure. In Duchenne muscular dystrophy, the use of steroids, spinal surgery to treat scoliosis, and respiratory support has improved survival. Patients are often choosing invasive ventilation, and median survival is now 35 years.15 In myotonic dystrophy type 1, about one-half of the deaths are caused by respiratory failure at a median age of 55 years.16 The electrophysiologist evaluating the
Nonarrhythmia cardiac clinical considerations
Electrocardiograms (ECGs) are a common screening test and have prognostic significance in some of the muscular dystrophies. Echocardiograms are indicated in the majority of referred patients. Cardiac magnetic resonance imaging may allow earlier diagnosis. Cardiac magnetic resonance circumferential strain detects early involvement in Duchenne muscular dystrophy.19 The cardiac magnetic resonance signal-to-noise ratio variance, a measure of myocardial fibrosis heterogeneity, correlates with
Bradycardias, conduction disease, and the use of pacemakers
In muscular dystrophies in which the primary cardiac manifestation is a dilated cardiomyopathy including Duchenne, Becker, and limb-girdle types 2C−2F and 2I, the likelihood of conduction disease is proportional to the severity of ventricular dysfunction. The need for pacemakers in these muscular dystrophies is limited and described in single patient case reports.
In muscular dystrophies in which the primary cardiac manifestation is conduction disease including myotonic, Emery-Dreifuss, and
Atrial arrhythmias
Atrial arrhythmias including tachycardia, flutter, and fibrillation are observed in muscular dystrophies. In Duchenne, Becker, and limb-girdle types 2C−2F and 2I, atrial arrhythmias occur after the development of a dilated cardiomyopathy or as a consequence of respiratory failure and cor pulmonale.
In muscular dystrophies associated with conduction involvement, atrial arrhythmias are common. Up to 15% of a myotonic dystrophy type 1 cohort with a median age of 41 years developed atrial
Ventricular arrhythmias, sudden death, and the use of ICDs
Ventricular arrhythmias and sudden death occur in the muscular dystrophies. In Duchenne and Becker muscular dystrophy, ventricular premature beats and nonsustained ventricular tachycardia are observed primarily in patients who have a dilated cardiomyopathy. Similar findings are anticipated but less well studied in the limb-girdle muscular dystrophies types 2C−2F and 2I. Sustained ventricular arrhythmias are described. In Duchenne muscular dystrophy, sudden death occurs primarily in patients
Future directions and conclusions
In all the muscular dystrophies, a better understanding of the genetic causes and molecular pathogenesis opens a potential for future gene-based therapies. In the interim, there remains a need for studies to determine risk factors for arrhythmias and sudden death and to assess the efficacy of therapies. In these diseases, it is unlikely that randomized controlled trials will be done. Rather, clinical decisions will need to be based on nonrandomized registries and observational treatment trials
References (28)
- et al.
Diagnostic work-up and risk stratification in X-linked dilated cardiomyopathies caused by dystrophin defects
J Am Coll Cardiol
(2011) - et al.
Myotonic dystrophy type 2 (DM2) and related disorders: report of the 180th ENMC workshop including guidelines on diagnostics and management
Neuromusc Disord
(2011) - et al.
Lamin A/C gene and the heart: how genetics may impact clinical care
J Am Coll Cardiol
(2008) - et al.
Heart transplantation in 7 patients from a single family with limb-girdle muscular dystrophy caused by lamin A/C mutation
Int J Cardiol
(2009) - et al.
Risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers: a European cohort study
J Am Coll Cardiol
(2012) - et al.
Emery-Dreifuss muscular dystrophy
Hand Clin Neurol
(2011) - et al.
Circumferential strain analysis identifies strata of cardiomyopathy in Duchenne muscular dystrophy: a cardiac magnetic resonance tagging study
J Am Coll Cardiol
(2009) - et al.
Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up
Am Heart J
(2007) - et al.
Clinical outcomes after cardiac transplantation in muscular dystrophy patients
J Heart Lung Transplant
(2010) - et al.
Mortality in myotonic dystrophy patients in the area of prophylactic pacing devices
Int J Cardiol
(2011)
Left ventricular dysfunction and cardiac arrhythmias are frequent in type 2 myotonic dystrophy: a case control study
Neuromusc Disord
Cardiomyopathy of Duchenne muscular dystrophy: current understanding and future directions
Muscle Nerve
Cardiac pathology exceeds skeletal muscle pathology in two cases of limb-girdle muscular dystrophy type 2I
Muscle Nerve
Distinct pathophysiological mechanisms of cardiomyopathy in hearts lacking dystrophin or the sarcoglycan complex
FASEB J
Cited by (98)
The Genetic Evaluation of Dilated Cardiomyopathy
2023, Structural HeartAtrial Flutter in Particular Patient Populations
2022, Cardiac Electrophysiology ClinicsCitation Excerpt :Ablate and pace (with biventricular or dual chamber pacemakers) may be an important option among patients with atypical AFl and poorly controlled ventricular rate.38 Muscular dystrophies encompass a wide spectrum of inherited disorders characterized by progressive involvement of the skeletal muscles, and most of the muscular dystrophies also affect the myocardium.43,44 Disorders associated with mutations of dystrophin and dystrophin-associated glycoproteins (eg, Duchenne and Becker muscular dystrophies), which connect the myocyte’s contractile proteins to the sarcolemma, are associated with progressive loss of myocardiocytes and fibrofatty replacement, leading to dilated cardiomyopathy; arrhythmias (both ventricular and supraventricular) occur late in the disease course.43
2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: Developed by the Task Force on Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA)
2022, Revista Espanola de Cardiologia
The research was supported by grants from the Muscular Dystrophy Association (Tucson, AZ).
This manuscript was processed by a guest editor.